Comparative study of hyoscine doses as antisialagogue for patients receiving ketofol sedation undergoing colonoscopy procedures.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201505001102479

Enrollment

150

Registered

2015-04-15

Start date

2015-04-18

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Health salivation

Interventions

5 mg (group A)

10 mg (group B)

20 mg (group C)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (ASA) physical status ¿-¿¿¿ patients of both sexes aged 20-60 years scheduled for therapeutic or diagnostic colonoscopy under ketofol sedation

Exclusion criteria

Exclusion criteria: Patients with allergy to study drugs, cardiovascular disease (hypertension, tachycardia, congestive heart failure, and coronary artery disease), and decompensated hepatic or renal failure, glaucoma and prostatic patients

Design outcomes

Primary

Measure	Time frame
degree of salivation	—

Countries

Egypt

Contacts

Public ContactHassan Ali

Lecturer of anesthesia and pain management, Anesthesia department, Cairo university

hassan364@hotmail.com+201001733687

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026